Moreover, we added serum Cr and the use of the SGLT2 inhibitor or insulin as covariates in the multivariate logistic regression analysis as additional analysis and the results did not change, which showed that patients with a lower level of glutamic acid remained at significantly higher risk of sarcopenia after adjustment for serum Cr and the SGLT2 inhibitor (adjusted OR 4.34, 95% CI 1.07–17.65, p = 0.04), or for serum Cr and insulin (adjusted OR 4.42, 95% CI 1.08–18.08, p = 0.039). Here, SLC5A2 is linked to sarcopenia.